No Data
No Data
No Data
No Data
No Data
HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance
Biotech psychedelics company HAVN Life Sciences Inc. (OTC:HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean ("ABO"), previously announced on July 2
Benzinga Real-time NewsAug 19, 2022 16:06 ET
HAVN Life Sciences announces 1-for-30 reverse stock split
HAVN Life Sciences (OTCPK:HAVLF) announced Friday the reverse stock split at 1-for-30 of its shares. Stock will begin trading on a consolidated basis on August 3, 2022, with a new CUSIP number. As
Seeking AlphaJul 29, 2022 17:01 ET
HAVN Life Announces a 30:1 Consolidation of its Common Shares
VANCOUVER, British Columbia, July 29, 2022 (GLOBE NEWSWIRE) -- HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") a biotechnology company pursuing standardize
GlobeNewswireJul 29, 2022 16:35 ET
HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC:HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its the
Benzinga Real-time NewsJun 28, 2022 15:30 ET
HAVN Life enters supply agreement with MPB Group
HAVN Life Sciences (OTCPK:HAVLF) enters into a supply partnership with a comprehensive outpatient mental health clinic, MPB Group. MPB Group is partnered with Healing Escapes Foundation retreats, a n
Seeking AlphaJun 28, 2022 07:39 ET
HAVN Life Sciences Inc. to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022
VANCOUVER, BC / ACCESSWIRE / April 30, 2022 / HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE:5NP), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigat
AccesswireApr 30, 2022 08:05 ET
No Data
No Data